New number of shares and votes in Senzime AB (publ)

The number of shares and votes in Senzime has increased during the month of July due to the directed issue if shares resolved by the board by on July 5, 2023, as authorized by the general meeting on May 16 2023.

As of July 31, 2023, the total number of shares in Senzime amounts to 87,622,614 (previously 82,566,660 shares), with one vote each. The share capital amounts to SEK 10,952,826.75 (previously SEK 10,320,832.50).
As of July 31, 2023, Senzime holds no treasury shares.

For further information, please contact:

Philip Siberg, CEO of Senzime AB
Phone: +46 (0) 707 90 67 34, e-mail: [email protected]

About Senzime

Senzime is a Swedish medical device company that develops, manufactures, and markets CE- and FDA-cleared patient monitoring systems. Senzime’s employees worldwide are committed to the vision of a world without anesthesia- and respiratory-related complications. The company markets an innovative portfolio of solutions, including the TetraGraph® and ExSpiron® 2Xi for real-time monitoring of neuromuscular and respiratory functions, typically under and after surgery. The goal is to help eliminate in-hospital complications, and radically reduce health care costs related to surgical and high acuity procedures.

Senzime targets a market opportunity valued more than SEK 40 billion per year, and operates with sales teams in the world’s leading markets. The company’s shares are listed on Nasdaq Stockholm Main Market (SEZI). More information is available at senzime.com.

This information is information that Senzime is obliged to make public pursuant to the Financial Instruments Trading Act. The information was submitted for publication at 2023-07-31 09:00 CEST.

Downloads
Contact

Philip Siberg, CEO of Senzime

+46 (0) 70 790 6734
[email protected]
 

Subscribe

Click here to sign up to our latest news.

Subscription service
en sv de